RSC-1255 / RasCal Therap - LARVOL DELTA

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=134 | Recruiting | Sponsor: RasCal Therapeutics, Inc. | Trial completion date: Sep 2025 ➔ Jan 2027 | Trial primary completion date: Jul 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Brain Cancer • Colon Cancer • Colorectal Cancer • Glioblastoma • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (clinicaltrials.gov) - P1 | N=134 | Recruiting | Sponsor: RasCal Therapeutics, Inc. | Phase classification: P1a/1b ➔ P1 | Trial completion date: Mar 2024 ➔ Sep 2025 | Trial primary completion date: Jan 2024 ➔ Jul 2025

Metastases • Phase classification • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Glioblastoma • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (clinicaltrials.gov) - P1a/1b; N=134; Recruiting; Sponsor: RasCal Therapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Brain Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Glioblastoma • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor